TG ENABLE
The purpose of this study is to evaluate safety, effectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting.
Inclusion Criteria:
Participants with a confirmed Multiple Sclerosis (MS) diagnosis who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion.
For more information, contact Allison Clarke at aemborsky@dentinstitute.com or 716-558-3543